{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T12:06:00Z","timestamp":1749470760888,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10147-020-01841-4","type":"journal-article","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T14:02:21Z","timestamp":1609509741000},"page":"764-769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Grade group 2 (10%\u2009\u2265\u2009GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3454-3658","authenticated-orcid":false,"given":"Masashi","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Hanazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Tochigi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyasu","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Funahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,1]]},"reference":[{"key":"1841_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Colombet M, Soerjomataram I et al (2018) Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer (Oxford, England: 1990) 103:356\u2013387. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.005","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"1841_CR2","unstructured":"National Cancer Information Center Information Servie in Japan https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/summary.html. Accessed 15 July 2020"},{"issue":"15","key":"1841_CR3","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy FC, Donovan JL, Lane JA et al (2016) 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa1606220","journal-title":"N Engl J Med"},{"issue":"3","key":"1841_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/jco.2014.55.1192","volume":"33","author":"L Klotz","year":"2015","unstructured":"Klotz L, Vesprini D, Sethukavalan P et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J ClinOncolOff J Am SocClinOncol 33(3):272\u2013277. https:\/\/doi.org\/10.1200\/jco.2014.55.1192","journal-title":"J ClinOncolOff J Am SocClinOncol"},{"issue":"10","key":"1841_CR5","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/s1470-2045(14)70361-4","volume":"15","author":"JA Lane","year":"2014","unstructured":"Lane JA, Donovan JL, Davis M et al (2014) Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 15(10):1109\u20131118. https:\/\/doi.org\/10.1016\/s1470-2045(14)70361-4","journal-title":"Lancet Oncol"},{"issue":"18","key":"1841_CR6","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1200\/jco.2015.65.7759","volume":"34","author":"RC Chen","year":"2016","unstructured":"Chen RC, Rumble RB, Loblaw DA et al (2016) Active surveillance for the management of localized prostate cancer (cancer care ontario guideline): american society of clinical oncology clinical practice guideline endorsement. J ClinOncol Off J Am SocClinOncol 34(18):2182\u20132190. https:\/\/doi.org\/10.1200\/jco.2015.65.7759","journal-title":"J ClinOncol Off J Am SocClinOncol"},{"issue":"4","key":"1841_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. EurUrol 71(4):618\u2013629. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.003","journal-title":"EurUrol"},{"issue":"35","key":"1841_CR8","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/jco.2012.44.0586","volume":"30","author":"HB Carter","year":"2012","unstructured":"Carter HB, Partin AW, Walsh PC et al (2012) Gleason score 6 adenocarcinoma: should it be labeled as cancer? J ClinOncolOff J Am SocClinOncol 30(35):4294\u20134296. https:\/\/doi.org\/10.1200\/jco.2012.44.0586","journal-title":"J ClinOncolOff J Am SocClinOncol"},{"key":"1841_CR9","unstructured":"NCCN Guidelines, Prostate Cancer Version 2 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed 15 July 2020"},{"issue":"3","key":"1841_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.euo.2020.03.002","volume":"3","author":"F Preisser","year":"2020","unstructured":"Preisser F, Cooperberg MR, Crook J et al (2020) Intermediate-risk prostate cancer: stratification and management. EurUrolOncol 3(3):270\u2013280. https:\/\/doi.org\/10.1016\/j.euo.2020.03.002","journal-title":"EurUrolOncol"},{"issue":"8","key":"1841_CR11","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/pas.0000000000001497","volume":"44","author":"G van Leenders","year":"2020","unstructured":"van Leenders G, van der Kwast TH, Grignon DJ et al (2020) The 2019 international society of urological pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J SurgPathol 44(8):e87\u2013e99. https:\/\/doi.org\/10.1097\/pas.0000000000001497","journal-title":"Am J SurgPathol"},{"issue":"10","key":"1841_CR12","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/pros.23818","volume":"79","author":"M Kato","year":"2019","unstructured":"Kato M, Hirakawa A, Kobayashi YM et al (2019) The influence of the presence of intraductal carcinoma of the prostate on the grade group system\u2019s prognostic performance. Prostate 79(10):1065\u20131070. https:\/\/doi.org\/10.1002\/pros.23818","journal-title":"Prostate"},{"issue":"2","key":"1841_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/modpathol.2015.146","volume":"29","author":"M Kato","year":"2016","unstructured":"Kato M, Tsuzuki T, Kimura K et al (2016) The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation. Mod Pathol Off J US Can AcadPatholInc 29(2):166\u2013173. https:\/\/doi.org\/10.1038\/modpathol.2015.146","journal-title":"Mod Pathol Off J US Can AcadPatholInc"},{"issue":"6","key":"1841_CR14","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/pros.22786","volume":"74","author":"K Kimura","year":"2014","unstructured":"Kimura K, Tsuzuki T, Kato M et al (2014) Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 74(6):680\u2013687. https:\/\/doi.org\/10.1002\/pros.22786","journal-title":"Prostate"},{"issue":"4","key":"1841_CR15","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.eururo.2017.03.013","volume":"72","author":"LH Porter","year":"2017","unstructured":"Porter LH, Lawrence MG, Ilic D et al (2017) Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories. EurUrol 72(4):492\u2013495. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.013","journal-title":"EurUrol"},{"key":"1841_CR16","unstructured":"European Association of Urology Guideline, Prostate Cancer. 2020 https:\/\/uroweb.org\/guideline\/prostate-cancer\/?type=summary-of-changes. Accessed 19 July 2020"},{"key":"1841_CR17","volume-title":"TNM classification of malignant tumors","author":"JD Brierley","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumors, 8th edn. Wiley-Blackwell, Oxford","edition":"8"},{"issue":"10","key":"1841_CR18","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/s0046-8177(98)90423-3","volume":"29","author":"G Wilcox","year":"1998","unstructured":"Wilcox G, Soh S, Chakraborty S et al (1998) Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer. Hum Pathol 29(10):1119\u20131123. https:\/\/doi.org\/10.1016\/s0046-8177(98)90423-3","journal-title":"Hum Pathol"},{"issue":"4","key":"1841_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. EurUrol 71(4):630\u2013642. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.002","journal-title":"EurUrol"},{"issue":"6","key":"1841_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J et al (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18(6):695\u2013706","journal-title":"Stat Med"},{"key":"1841_CR21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141\u20131154","journal-title":"Ann Stat"},{"key":"1841_CR22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"1841_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/pros.22906","volume":"75","author":"T Zhao","year":"2015","unstructured":"Zhao T, Liao B, Yao J et al (2015) Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer? Prostate 75(3):225\u2013232. https:\/\/doi.org\/10.1002\/pros.22906","journal-title":"Prostate"},{"issue":"3","key":"1841_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bju.14935","volume":"125","author":"L Klotz","year":"2020","unstructured":"Klotz L (2020) Active surveillance in intermediate-risk prostate cancer. BJU Int 125(3):346\u2013354. https:\/\/doi.org\/10.1111\/bju.14935","journal-title":"BJU Int"},{"issue":"1","key":"1841_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.6004\/jnccn.2016.0004","volume":"14","author":"JL Mohler","year":"2016","unstructured":"Mohler JL, Armstrong AJ, Bahnson RR et al (2016) Prostate Cancer, Version 1.2016. J Natl Compr Cancer Netw JNCCN 14(1):19\u201330. https:\/\/doi.org\/10.6004\/jnccn.2016.0004","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"2","key":"1841_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.euo.2018.08.004","volume":"2","author":"SP Kim","year":"2019","unstructured":"Kim SP, Shah ND, Meropol NJ et al (2019) Recommendations of active surveillance for intermediate-risk prostate cancer: results from a national survey of radiation oncologists and urologists. EurUrolOncol 2(2):189\u2013195. https:\/\/doi.org\/10.1016\/j.euo.2018.08.004","journal-title":"EurUrolOncol"},{"issue":"8","key":"1841_CR27","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/modpathol.2017.29","volume":"30","author":"CF Kweldam","year":"2017","unstructured":"Kweldam CF, K\u00fcmmerlin IP, Nieboer D et al (2017) Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer. Mod Pathol Off J US Can AcadPatholInc 30(8):1126\u20131132. https:\/\/doi.org\/10.1038\/modpathol.2017.29","journal-title":"Mod Pathol Off J US Can AcadPatholInc"},{"issue":"1","key":"1841_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.juro.2016.07.076","volume":"197","author":"N Perlis","year":"2017","unstructured":"Perlis N, Sayyid R, Evans A et al (2017) Limitations in predicting organ confined prostate cancer in patients with gleason pattern 4 on biopsy: implications for active surveillance. J Urol 197(1):75\u201383. https:\/\/doi.org\/10.1016\/j.juro.2016.07.076","journal-title":"J Urol"},{"issue":"8","key":"1841_CR29","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1097\/pas.0000000000000235","volume":"38","author":"CC Huang","year":"2014","unstructured":"Huang CC, Kong MX, Zhou M et al (2014) Gleason score 3 + 4=7 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen. Am J SurgPathol 38(8):1096\u20131101. https:\/\/doi.org\/10.1097\/pas.0000000000000235","journal-title":"Am J SurgPathol"},{"issue":"11","key":"1841_CR30","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1097\/pas.0000000000001345","volume":"43","author":"S Sato","year":"2019","unstructured":"Sato S, Kimura T, Yorozu T et al (2019) Cases having a gleason score 3+4=7 with <5% of gleason pattern 4 in prostate needle biopsy show similar failure-free survival and adverse pathology prevalence to gleason score 6 cases in a radical prostatectomy cohort. Am J SurgPathol 43(11):1560\u20131565. https:\/\/doi.org\/10.1097\/pas.0000000000001345","journal-title":"Am J SurgPathol"},{"key":"1841_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejca.2016.07.012","volume":"66","author":"CF Kweldam","year":"2016","unstructured":"Kweldam CF, K\u00fcmmerlin IP, Nieboer D et al (2016) Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma. Eur J Cancer (Oxford, England: 1990) 66:26\u201333. https:\/\/doi.org\/10.1016\/j.ejca.2016.07.012","journal-title":"Eur J Cancer (Oxford, England: 1990)"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01841-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-020-01841-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01841-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T15:03:41Z","timestamp":1616252621000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-020-01841-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1841"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01841-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2021,1,1]]},"assertion":[{"value":"11 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest and no fund.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}